--- canonical_name: Lemongrass alternate_names: Cymbopogon citratus, Cymbopogon flexuosus, West Indian Lemongrass, East Indian Lemongrass, Lemon Grass, Fever Grass, Citronella Grass canonical_topic: Lemongrass to Treat Cancer short_topic_lc: lemongrass_cancer creation_date: 2026-0711-0002 creator_ai_fullname: Opus 4.8 --- # Lemongrass to Treat Cancer
Evidence Review created on 07/11/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** Cymbopogon citratus, Cymbopogon flexuosus, West Indian Lemongrass, East Indian Lemongrass, Lemon Grass, Fever Grass, Citronella Grass ## Motivation Lemongrass is a tall, citrus-scented grass grown across Asia and Africa and widely used to flavor teas, soups, and curries. Its lemony aroma comes mostly from citral, a fragrant oil that has drawn scientific attention because, in laboratory dishes, it can push certain cancer cells into self-destruction while appearing to spare many healthy cells. That single observation is the reason lemongrass is now discussed as a possible anti-cancer agent. Interest grew after a widely reported Israeli laboratory study showed that the amount of citral found in roughly a single cup of lemongrass tea could trigger blood-cancer cells to die in a dish. News of the finding spread quickly, and some people began brewing strong lemongrass tea in the hope of mimicking the experiment. Since then, dozens of laboratory and animal studies have explored lemongrass and citral against many cancer types. This review examines what that body of evidence actually shows, how the proposed effects are thought to work, and where the science currently stands. It focuses on the gap between promising laboratory signals and the absence of human treatment studies, and on the safety questions that matter for anyone considering concentrated lemongrass. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section collects high-level, directly relevant commentary and narrative overviews on lemongrass, its active compound citral, and their study in cancer. * [The Chemistry of Tom Yum Soup](https://www.mcgill.ca/oss/article/food-health/lemongrass-and-cancer) - Joe Schwarcz A science-communication essay from McGill University's Office for Science and Society that traces how a single laboratory finding on citral became a popular cancer-tea claim, and explains why laboratory concentrations do not translate to what reaches a tumor in the body. * [Lemongrass](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/lemongrass) - Memorial Sloan Kettering Cancer Center A cancer center's integrative-medicine monograph summarizing purported benefits, documented adverse effects, and drug-interaction cautions, with an explicit note that human evidence is limited and anticancer claims rest on laboratory work. * [Targets and pathways involved in the antitumor activity of citral and its stereo-isomers](https://pubmed.ncbi.nlm.nih.gov/31981590/) - Bailly, 2020 A narrative review mapping the specific molecular targets behind citral's laboratory anticancer activity, and candidly noting the compound's low stability, poor bioavailability, and lack of selectivity as barriers to real-world use. * [Chemical Properties and Therapeutic Potential of Citral, a Monoterpene Isolated from Lemongrass](https://pubmed.ncbi.nlm.nih.gov/31880247/) - Sharma et al., 2021 A narrative review covering how citral is extracted, absorbed, and metabolized, alongside its reported antimicrobial, antioxidant, and anticancer properties, useful for understanding why the molecule is chemically fragile. * [Review of phytomedicine, phytochemistry, ethnopharmacology, toxicology, and pharmacological activities of Cymbopogon genus](https://pubmed.ncbi.nlm.nih.gov/36105217/) - Tibenda et al., 2022 A broad narrative review of the lemongrass genus that situates the anticancer research within the plant's wider traditional and pharmacological profile, including toxicity considerations. ## Grokipedia [Cymbopogon citratus](https://grokipedia.com/page/Cymbopogon_citratus) The primary dedicated entry for lemongrass, covering its botany, chemistry (including citral content), traditional uses, and a summary of pharmacological research, providing broad background context for the intervention. ## Examine No dedicated Examine.com article for lemongrass was found. Examine.com focuses on supplements and nutrients with a substantial human evidence base, and lemongrass is not currently among its covered entries. ## ConsumerLab No dedicated ConsumerLab.com review for lemongrass was found. ConsumerLab.com publishes independent product-quality tests, and it does not currently list a lemongrass review. ## Systematic Reviews The following systematic reviews concern lemongrass (*Cymbopogon citratus*) and the wider *Cymbopogon* genus; note that none evaluate lemongrass as a cancer treatment, reflecting the absence of pooled clinical oncology evidence. * [Effectiveness of Lemon Verbena (Cymbopogon citratus) in Oral Candidiasis: A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/39286661/) - Cuenca-León et al., 2024 A systematic review of in vitro and animal studies finding limited but consistent antifungal activity of *Cymbopogon citratus* against oral thrush; it illustrates the plant's biological activity while underscoring that even for this use, clinical trials are lacking. * [Antifungal Properties of Essential Oils Derived from the Genus Cymbopogon: A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/37574454/) - Butzge et al., 2023 A systematic review across nine *Cymbopogon* species identifying *C. citratus* as the most-studied and most potent, and linking activity to citral and related constituents, relevant for understanding the plant's overall pharmacological potency. * [Herbs and Spices - Biomarkers of Intake Based on Human Intervention Studies - A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/31143299/) - Vázquez-Fresno et al., 2019 A systematic review of human intake studies covering 25 culinary herbs and spices including lemongrass, notable here for documenting how little controlled human data exist on lemongrass consumption of any kind. ## Mechanism of Action Lemongrass is a plant, not a single drug, and its studied anticancer activity is attributed largely to citral, a monoterpene (a small, volatile plant compound) that makes up roughly 65–85% of lemongrass essential oil. Citral is itself a mixture of two mirror-image forms, geranial (the trans-isomer) and neral (the cis-isomer), with geranial generally the more active. In laboratory studies, citral's proposed anticancer actions rest on several converging mechanisms: * **Oxidative stress and apoptosis:** Citral drives a build-up of reactive oxygen species (ROS — unstable oxygen molecules that damage cell components) inside cancer cells, causing DNA damage and triggering apoptosis (programmed cell death, the body's orderly self-destruct process). This is executed through activation of caspase-3 (an enzyme that carries out cell death). * **Disruption of cell division:** Citral inhibits the assembly of tubulin into microtubules — the internal scaffolding cells need to divide — in a manner loosely resembling the drug colchicine, stalling proliferating cells. * **Enzyme targets tied to treatment resistance:** Citral inhibits MARK4 (a kinase enzyme that helps regulate cell division) and ALDH1A3 (an enzyme linked to cancer stem-cell growth and chemotherapy resistance). Blocking ALDH1A3 is one proposed route by which lemongrass extracts may re-sensitize resistant cancer cells to chemotherapy in laboratory models. Competing mechanistic views exist. Some studies report that lemongrass essential oil's effects cannot be fully reproduced by purified citral alone, suggesting other constituents (such as geraniol or plant polysaccharides) contribute, while other work argues citral is the dominant actor. There is also debate over selectivity: several papers report preferential killing of cancer cells, whereas others show measurable toxicity to normal human blood cells at similar concentrations, indicating the "spares healthy cells" mechanism is not absolute. As a pharmacological compound, citral has notable limitations. It is chemically unstable — an α,β-unsaturated aldehyde that degrades on exposure to air and light — has low oral bioavailability, and is rapidly metabolized in the gut and liver (including oxidation and conjugation to a biliary glucuronide, with handling influenced by CYP450 enzymes (liver enzymes that break down many drugs) and glutathione-S-transferase (a detoxification enzyme family)). Its plasma half-life in humans is not well characterized but is thought to be short, and it does not concentrate selectively in tumor tissue. ## Historical Context & Evolution Lemongrass has a long history unrelated to cancer, which frames how it came to be studied as a possible treatment. * **Original intended use:** Lemongrass has been used for centuries as a culinary flavoring and in traditional medicine systems across Asia, Africa, and Latin America — as a tea for digestion, fever, sleep, and anxiety, and topically as an insect repellent and antimicrobial. Its essential oil is also a longstanding fragrance and food-additive ingredient. * **Route into cancer research:** Interest in an anticancer role grew from mechanistic curiosity about citral. A 2005 laboratory study from Ben Gurion University in Israel (Dudai and colleagues, published in *Planta Medica*) reported that citral, at a concentration comparable to that in a cup of tea brewed from about 1 gram of lemongrass, induced apoptosis in several blood-cancer cell lines. The finding that a common food compound could do this at "tea-strength" concentrations attracted wide public attention and seeded the idea of lemongrass tea as a cancer remedy. * **What the original research actually found:** The Israeli work documented apoptosis, DNA fragmentation, and caspase-3 activation in cultured hematopoietic cancer cells — a genuine laboratory effect. It did not test whether drinking lemongrass tea shrinks tumors in people, and the researchers themselves framed it as a mechanistic observation rather than a treatment claim. * **How opinion has evolved:** Since 2005, research has expanded to many cancer cell types and to a small number of mouse studies, some suggesting lemongrass extract can slow tumor growth and improve chemotherapy tolerance. At the same time, closer analysis has highlighted citral's instability, poor bioavailability, and imperfect selectivity. The current position is not that the early findings were "debunked," but that they remain confined to the laboratory and early animal stage, with the central open question — whether any of this translates to humans — still unanswered on both sides. ## Expected Benefits The benefits below are framed for a health- and longevity-oriented reader weighing an unproven option. A dedicated search of clinical, laboratory, and expert sources was performed before writing this section. The overriding finding is that no human clinical trials have tested lemongrass or citral as a cancer treatment; all evidence is from laboratory (in vitro, meaning in laboratory dishes) and animal (in vivo, meaning in living animals) studies. Evidence grades therefore reach no higher than Low. ### Low 🟩 #### Direct Cancer-Cell Apoptosis and Growth Inhibition Across many independent laboratory studies, lemongrass extract, its essential oil, and purified citral reduce the growth of and trigger apoptosis (programmed cell death) in a wide range of cancer cell lines, including colon, breast, prostate, stomach, lung, cervical, and blood cancers. The proposed basis is a build-up of reactive oxygen species, disruption of cell division, and activation of the cell-death enzyme caspase-3. Importantly, a few mouse studies extend this beyond the dish: oral lemongrass extract slowed the growth of implanted human colon-cancer and lymphoma tumors (xenografts — human tumors grown in mice) without evident harm to the animals. This grade is capped at Low because, despite consistent and repeated preclinical signals including animal data, there is no evidence in human cancer patients. **Magnitude:** In laboratory studies, citral induced apoptosis at roughly 44.5 µM (comparable to the amount in a cup of tea from about 1 gram of lemongrass), and essential-oil concentrations that halved cell survival typically fell in the tens of µg/mL range depending on the cell line; oral extract reduced mouse tumor size relative to untreated animals. ### Speculative 🟨 #### Enhancement of Conventional Chemotherapy In laboratory and animal models, lemongrass extract has been reported to increase the anticancer effect of standard chemotherapy — for example improving the activity of a common colon-cancer drug combination (FOLFOX, a folinic acid, fluorouracil, and oxaliplatin regimen) and of the prostate-cancer drug docetaxel, and helping reverse resistance to doxorubicin. The proposed mechanism includes inhibition of the resistance-linked enzyme ALDH1A3 and interference with drug-export pumps. No human studies have tested whether lemongrass improves chemotherapy outcomes, and any real-world combination raises interaction concerns rather than established benefit. #### Reduction of Chemotherapy Side Effects One mouse study reported that adding lemongrass extract to a colon-cancer chemotherapy regimen reduced the treatment-related weight loss seen in the animals, hinting at a protective effect on normal tissue. This is a single-model observation with a plausible antioxidant rationale but no human confirmation, so it is treated as speculative. #### Selective Toxicity Sparing Normal Cells ⚠️ Conflicted Some laboratory studies report that lemongrass and citral preferentially kill cancer cells while leaving healthy cells relatively unharmed, which would be highly desirable in a cancer therapy. However, other studies show meaningful toxicity to normal human white and red blood cells at comparable concentrations. Because the evidence directly conflicts and rests entirely on cell cultures, the notion of clean selectivity is speculative and explicitly contested. #### Antioxidant and Anti-Inflammatory Chemoprevention Lemongrass is rich in antioxidant and anti-inflammatory compounds, and dietary intake is sometimes proposed to lower long-term cancer risk by reducing oxidative and inflammatory damage. This is a mechanistic and population-level hypothesis with no controlled human cancer-prevention data for lemongrass specifically, and is included only as a speculative, mechanism-based possibility. ## Benefit-Modifying Factors Because no human efficacy data exist, factors that would modify benefit are necessarily inferred from citral's pharmacology. * **Genetic polymorphisms:** Variation in detoxification enzymes such as glutathione-S-transferase (which conjugates reactive aldehydes like citral) and CYP450 enzymes could influence how quickly citral is cleared, and therefore how much reaches any tissue — a theoretical modifier of any effect. * **Baseline biomarker levels:** Because the proposed mechanism runs through oxidative stress, a person's baseline antioxidant status and tumor redox state could plausibly influence responsiveness, though this has not been tested clinically. * **Sex-based differences:** No human data allow sex-specific benefit estimates; some laboratory work is cancer-type specific (e.g., prostate models are male-relevant, cervical and breast models female-relevant), but this reflects the model, not a demonstrated human sex difference. * **Pre-existing health conditions:** Impaired liver or kidney function could alter citral metabolism and clearance, indirectly affecting exposure; gastrointestinal absorption also limits how much oral citral becomes available. * **Age-related considerations:** Older adults, including those at the upper end of the target range, tend to have reduced hepatic and renal clearance and more concurrent medications, which could change citral handling; no age-specific efficacy data exist. ## Potential Risks & Side Effects Risks are framed for a proactive adult who might consider concentrated lemongrass. A dedicated search of drug-reference and clinical sources (including Memorial Sloan Kettering's herb monograph and general pharmacology references) was performed. Culinary use of lemongrass is broadly regarded as safe; the risks below concern concentrated teas, extracts, and essential oil, and the treatment context itself. ### High 🟥 🟥 🟥 #### Skin Sensitization and Allergic Contact Dermatitis Citral is a well-documented fragrance allergen, and lemongrass essential oil applied to skin can cause allergic contact dermatitis (an itchy, inflamed skin rash). A published case describes a massage therapist who developed a delayed rash from topical lemongrass oil that recurred when she later drank lemongrass tea, indicating cross-reactivity between topical and oral exposure. This is among the best-established human harms. **Magnitude:** Citral is a common cause of positive fragrance patch tests, with reported positivity on the order of a few percent in dermatitis-clinic populations. #### Opportunity Cost of Replacing Proven Cancer Therapy The most serious risk in a cancer context is not a direct toxicity but the danger of using lemongrass in place of, or to the neglect of, treatments with demonstrated survival benefit. Because no human evidence shows lemongrass treats cancer, substituting it for effective therapy could allow a treatable cancer to progress. This risk is graded High on the strength of the well-established general principle that delaying proven oncologic care worsens outcomes. **Magnitude:** Not quantified in available studies. ### Medium 🟥 🟥 #### Gastrointestinal Irritation at High Doses Concentrated lemongrass preparations and essential oil can irritate the stomach lining and cause nausea or abdominal discomfort, particularly when tea is brewed very strongly or oil is ingested. In high doses, lemongrass essential oil has been reported to damage stomach mucous membranes. **Magnitude:** Reported with essential-oil and high-dose extract exposure; ordinary culinary amounts are not associated with these effects. #### Blood-Sugar Lowering (Hypoglycemia) Animal studies indicate lemongrass and citral can lower blood glucose. For someone who is fasting, eating little, or taking glucose-lowering medication, concentrated intake could contribute to unexpectedly low blood sugar (hypoglycemia — abnormally low blood glucose that can cause shakiness, confusion, or fainting). **Magnitude:** Dose-dependent glucose reductions have been shown in rodent studies; human dose-response is not established. ### Low 🟥 #### Hepatic and Renal Effects at High Doses At high doses, lemongrass essential oil has been associated with liver injury in animal models, and excessive intake of lemongrass tea has been linked to effects on kidney function. These effects appear tied to large, non-culinary exposures rather than normal dietary use. **Magnitude:** Documented mainly in animal high-dose studies and isolated human reports of excess tea intake. #### Dizziness, Drowsiness, Dry Mouth, and Excess Urination Oral lemongrass has been associated with dizziness, drowsiness, dry mouth, increased urination, and increased appetite. These are generally mild and reversible but relevant for driving, hydration, and older adults prone to falls. **Magnitude:** Reported as common, mild oral effects in integrative-medicine references; frequency not precisely quantified. ### Speculative 🟨 #### Pregnancy and Uterine-Stimulation Risk Citral and some lemongrass constituents have been proposed to have hormone-like or uterine-stimulating (emmenagogue) activity, raising a theoretical concern about concentrated use in pregnancy. Evidence is largely traditional and animal-based rather than controlled human data. #### Essential-Oil Ingestion Toxicity and Aspiration Swallowing undiluted essential oil, or inhaling it in a way that lets oil enter the airway, can cause chemical injury and, rarely, aspiration-type pneumonia — a general hazard of concentrated essential oils rather than a lemongrass-specific finding, and not systematically studied for lemongrass. #### Drug-Metabolism Interactions Increasing Toxicity ⚠️ Conflicted Because citral and myrcene are handled by CYP450 and glutathione-S-transferase enzymes, above-culinary intake could in theory raise blood levels or side effects of drugs sharing those pathways. Reference sources list this as a precaution while simultaneously noting that no such interactions have actually been reported, so the evidence is conflicting and speculative. ## Risk-Modifying Factors * **Genetic polymorphisms:** Reduced-function variants in glutathione-S-transferase or relevant CYP450 enzymes could slow citral clearance and heighten the chance of dose-related effects or drug interactions. * **Baseline biomarker levels:** Baseline liver enzymes, kidney function, and fasting glucose set the margin of safety; someone with already-elevated liver enzymes or a tendency to low blood sugar has less room before high-dose lemongrass causes a problem. * **Sex-based differences:** No reliable human data establish sex-specific risk differences for lemongrass; the theoretical pregnancy and uterine concern is female-specific. * **Pre-existing health conditions:** Liver disease, kidney disease, diabetes managed with glucose-lowering drugs, and known fragrance or citral allergy all raise the risk profile of concentrated use. * **Age-related considerations:** Older adults, including those at the upper end of the target range, more often have reduced organ clearance, polypharmacy, and fall risk from dizziness or drowsiness, increasing susceptibility to adverse effects. ## Key Interactions & Contraindications * **Prescription drug interactions:** Concentrated lemongrass may theoretically affect drugs metabolized by CYP450 liver enzymes — including certain statins (e.g., simvastatin, atorvastatin), calcium-channel blockers (e.g., amlodipine, diltiazem), and some chemotherapy agents (e.g., docetaxel, cyclophosphamide) — as well as drugs handled by glutathione-S-transferase, potentially altering their levels. **Severity: caution.** **Clinical consequence:** possible increased drug side effects. **Mitigation:** keep to culinary amounts and separate concentrated intake from medication timing; anyone on cancer therapy should involve their oncologist. * **Over-the-counter medication interactions:** Additive effects are plausible with over-the-counter sedatives or antihistamines (e.g., diphenhydramine, doxylamine), adding to drowsiness, and with high-dose non-steroidal anti-inflammatory drugs (e.g., ibuprofen, naproxen), adding to stomach-lining irritation. **Severity: caution.** **Mitigation:** avoid combining strong lemongrass preparations with sedating products before driving. * **Supplement interactions:** Combining concentrated lemongrass with other liver-loading botanicals may add to hepatic burden. **Severity: monitor.** * **Supplements with additive effects:** Blood-sugar-lowering supplements (e.g., berberine, cinnamon extract, alpha-lipoic acid) could add to lemongrass's glucose-lowering tendency; sedative herbs (e.g., valerian, kava) could add to drowsiness. **Severity: caution** for additive hypoglycemia or sedation. * **Other intervention interactions:** In laboratory models, lemongrass alters the handling of chemotherapy agents (e.g., doxorubicin, oxaliplatin-based regimens); whether this helps or harms in people is unknown, making unsupervised combination with active chemotherapy a specific concern. **Severity: caution to absolute contraindication without oncology oversight.** * **Populations who should avoid or use caution:** Pregnant or breastfeeding individuals; people with significant hepatic impairment (e.g., Child-Pugh Class B or C); people with chronic kidney disease; individuals with diabetes on insulin or sulfonylureas; those with known citral or fragrance allergy; and anyone actively undergoing cancer treatment without their oncologist's knowledge. ## Risk Mitigation Strategies * **Keep to culinary or mild tea amounts:** Restricting lemongrass to food seasoning or occasional mild tea, rather than concentrated extracts or ingested essential oil, avoids the doses linked to gastrointestinal, hepatic, and renal effects. * **Never ingest undiluted essential oil:** Avoiding oral use of concentrated lemongrass essential oil prevents chemical injury to the mouth, throat, and stomach and the rare risk of airway injury. * **Patch-test topical use:** Applying diluted lemongrass oil to a small skin area first, and discontinuing if redness or itching appears, reduces the chance of allergic contact dermatitis; those with prior fragrance-allergy reactions should avoid it. * **Monitor blood sugar if at risk:** For people on glucose-lowering medication, checking blood glucose when adding regular strong lemongrass tea guards against additive hypoglycemia; the strategy targets the blood-sugar-lowering effect. * **Do not substitute for cancer treatment:** Treating lemongrass strictly as an adjunct to be discussed with an oncologist — never as a replacement for evidence-based therapy — directly addresses the highest-severity risk of a treatable cancer progressing. * **Review interacting medications:** Checking with a pharmacist before combining concentrated lemongrass with CYP450-metabolized drugs, sedatives, or blood-sugar-lowering agents mitigates interaction-related side effects. ## Therapeutic Protocol There is no validated therapeutic protocol for lemongrass as a cancer treatment, because no human treatment studies exist; what follows describes how it is used in practice and by integrative practitioners, presented without endorsement. * **Conventional oncology position:** Mainstream cancer care does not use lemongrass as a treatment and positions it, at most, as a culinary food or a flavoring; any anticancer use is considered unproven. **Severity of evidence gap:** no clinical dosing exists. * **Integrative and traditional-use approach:** Some integrative practitioners and traditional systems use lemongrass tea (commonly brewed from roughly 1–2 grams of dried or fresh stalk per cup) as a general wellness or adjunctive tonic; the widely publicized Israeli laboratory work is often cited as the rationale for a "one to a few cups daily" pattern. No clinic or expert has established this as an effective anticancer dose. * **Best time of day:** No evidence supports a specific optimal time; because of mild sedative and diuretic tendencies, some users prefer earlier in the day to avoid nighttime urination, while others use it in the evening for its calming reputation. * **Half-life considerations:** Citral is chemically unstable and rapidly metabolized, with a short (poorly characterized) human half-life, which is one reason single large doses are unlikely to sustain meaningful tissue levels. * **Single versus split dosing:** Given rapid metabolism, habitual users typically split intake across the day (e.g., a cup morning and evening) rather than take one large dose, though this reflects practice rather than evidence. * **Genetic considerations:** Detoxification-enzyme variants (glutathione-S-transferase, CYP450) could influence citral exposure and tolerability, but no pharmacogenetic dosing guidance exists. * **Sex-based considerations:** No human data support sex-specific dosing; the pregnancy caution is the main sex-specific point. * **Age-related considerations:** Older adults, including those at the upper end of the target range, may prefer more conservative amounts given slower clearance and fall risk from drowsiness or dizziness. * **Baseline biomarker considerations:** Checking baseline liver enzymes, kidney function, and fasting glucose before any concentrated, sustained use lets a user gauge tolerability. * **Pre-existing condition considerations:** People with liver disease, kidney disease, or medication-managed diabetes should be especially conservative or avoid concentrated use. ## Discontinuation & Cycling * **Lifelong versus short-term:** There is no established treatment course; lemongrass is a food and can be used or stopped freely, and no evidence supports long-term "therapeutic" continuation for cancer. * **Withdrawal effects:** No withdrawal syndrome is known; stopping lemongrass is not associated with rebound or dependence. * **Tapering:** No tapering is required given the absence of dependence or physiological adaptation. * **Cycling:** No evidence supports cycling for efficacy; any perceived benefit rationale is theoretical, so cycling is neither established nor necessary. ## Sourcing and Quality * **Form and source:** Lemongrass is available as fresh or dried culinary stalk, tea bags, powdered extract, and concentrated essential oil; the safety and appropriate-use profile differs sharply, with essential oil being the most hazardous if ingested. * **What to look for:** For teas and extracts, third-party testing for pesticide residues, heavy metals, and microbial contamination is valuable because lemongrass is a field-grown crop; for essential oil, look for clearly stated citral (geranial plus neral) content and labeling that it is not for internal use. * **Reputable options:** Established culinary and herbal-tea brands and reputable essential-oil suppliers that provide certificates of analysis are preferable; there are no specialized "pharmaceutical-grade" lemongrass anticancer products, and any product marketed explicitly as a cancer cure should be treated as a red flag. * **Formulation note:** Because citral is unstable and poorly absorbed, much preclinical research uses engineered formulations (nanoparticles, encapsulation) that are not equivalent to teas or over-the-counter oils; consumer products do not replicate these. ## Practical Considerations * **Time to effect:** There is no established time to any anticancer effect because none is demonstrated in humans; general wellness effects some users report (calming, digestive comfort) are immediate-to-days but unrelated to cancer. * **Common pitfalls:** The main pitfalls are overconcentrating tea or ingesting essential oil in pursuit of "laboratory" citral levels, and — most seriously — using lemongrass as a substitute for proven treatment based on cell-culture headlines. * **Regulatory status:** Lemongrass is regulated as a food and food additive and is generally recognized as safe for culinary use; it is not approved as a drug or cancer treatment anywhere, and any marketed cancer claim is an unapproved, off-label consumer claim. * **Cost and accessibility:** Lemongrass is inexpensive and widely available in grocery stores and as tea, so cost is not a barrier; this accessibility is itself a reason exaggerated cancer claims spread easily. ## Interaction with Foundational Habits * **Sleep:** The interaction is plausibly direct and mild. Lemongrass has a traditional calming, sedative reputation and animal data suggest sedative effects, so evening tea may aid relaxation; however, its mild diuretic tendency can prompt nighttime urination that disrupts sleep, so timing and volume matter. * **Nutrition:** The interaction is mostly indirect. Lemongrass is a low-calorie flavoring that fits most dietary patterns; taken as concentrated tea it may modestly lower blood sugar, so pairing with balanced meals is sensible for those prone to hypoglycemia, and it should not be relied on as a nutrient source. * **Exercise:** The interaction is indirect and minor. There is no evidence lemongrass blunts or enhances training adaptations; its mild blood-pressure- and glucose-lowering tendencies mean well-hydrated, fed use around exercise is prudent, and an ongoing trial is examining lemongrass and aerobic performance. * **Stress management:** The interaction is plausibly direct. Aromatherapy and tea use of lemongrass are traditionally associated with reduced anxiety and stress, though a human study found lemongrass tea did not measurably lower anxiety, so any calming effect may be modest or non-specific; it can complement, not replace, core stress practices. ## Monitoring Protocol & Defining Success Because lemongrass is not a proven treatment, "success" cannot be defined as a cancer outcome; monitoring here is oriented to safety for anyone using concentrated, sustained amounts. Baseline testing before starting concentrated use establishes a personal reference for the organs most relevant to citral handling and its side effects. Baseline labs to consider before sustained concentrated use are liver enzymes, kidney function, and fasting glucose. Ongoing monitoring, if concentrated use continues, is reasonable at roughly every 6–12 months, or sooner (for example, at 4–8 weeks) if symptoms such as unusual fatigue, jaundice, or low-blood-sugar episodes appear. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | ALT & AST | ALT ~10–26 U/L; AST ~10–26 U/L | Detects liver stress from high-dose essential oil or extract | ALT = alanine aminotransferase, AST = aspartate aminotransferase (liver enzymes). Conventional labs often flag only >40 U/L; functional ranges are tighter. Best drawn fasting; recheck if fatigue or jaundice appears | | Fasting glucose | 75–90 mg/dL | Tracks the blood-sugar-lowering tendency, especially with diabetes medication | Requires 8–12 hour fast; pair with HbA1c (a 3-month average blood-sugar marker) if diabetic | | eGFR & creatinine | eGFR >90 mL/min/1.73m²; creatinine mid-normal | Screens for kidney effects linked to excessive lemongrass tea | eGFR = estimated glomerular filtration rate (a kidney-function score). Hydration and recent heavy exercise affect creatinine; avoid intense exercise the day before | | Complete blood count (CBC) | Within lab normal, stable over time | General safety screen given laboratory reports of effects on blood cells | CBC = a general blood-cell panel. No fasting required; useful mainly to confirm stability over time | Qualitative markers to track alongside labs: * Energy levels and any unusual or persistent fatigue * Digestive comfort versus nausea or stomach upset * Skin reactions (rash, itching) with topical or oral use * Symptoms of low blood sugar such as shakiness, sweating, or lightheadedness * Sleep quality and any nighttime urination ## Emerging Research Research on lemongrass and citral in cancer is expanding but remains preclinical; the emphasis is on chemistry and delivery rather than patient outcomes, and both encouraging and discouraging directions are active. * **No registered oncology trials:** A search of ClinicalTrials.gov returns no interventional cancer-treatment trials of lemongrass or citral. Registered human lemongrass trials are in unrelated areas — for example an aerobic-performance study ([NCT07195240](https://clinicaltrials.gov/study/NCT07195240), ~40 participants, recruiting) and a completed smoking-cessation biomarker study ([NCT07366294](https://clinicaltrials.gov/study/NCT07366294), 200 participants) — indicating human lemongrass research exists but not in oncology. * **Improved delivery to overcome citral's weaknesses:** Because citral is unstable and poorly absorbed, much new work engineers nanoparticle and encapsulated formulations to raise its effective dose; for example, alginate-nanoparticle citral against melanoma and breast-cancer cell lines ([Karami et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39427126/)) and solid lipid nanoparticle lemongrass oil ([Ali et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37641691/)). These could strengthen the case if they translate, but remain laboratory-stage. * **Chemotherapy-resistance targets:** Work on citral's inhibition of the resistance-linked enzyme ALDH1A3 and the cell-division kinase MARK4 ([Bailly, 2020](https://pubmed.ncbi.nlm.nih.gov/31981590/)) points to a possible role in re-sensitizing resistant tumors; this is a direction that could either mature into rational drug design or stall on citral's poor selectivity. * **Studies that could weaken the case:** Research documenting citral's toxicity to normal human blood cells and its lack of tumor selectivity ([Mendes Hacke et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35227781/)) represents the counter-direction — findings that, if confirmed, argue against a viable therapeutic window for whole lemongrass or crude citral. * **Future direction — human pharmacokinetics:** A key unresolved question is whether any citral from tea or extract reaches tumors at active concentrations in people; until human absorption and distribution are characterized, laboratory potency cannot be interpreted as therapeutic promise. ## Conclusion Lemongrass is a common culinary grass whose lemony oil, citral, can make cancer cells self-destruct in laboratory dishes and can slow implanted tumors in a small number of animal studies. That laboratory signal is real and has been repeated across many cancer types, which is why the idea of lemongrass as a cancer treatment persists. The proposed actions — driving damaging oxidative stress inside cancer cells, disrupting cell division, and interfering with enzymes tied to treatment resistance — are biologically coherent. The decisive limitation is that none of this has been tested as a treatment in people. There are no human studies showing that drinking lemongrass tea or taking its extract shrinks tumors or helps patients live longer, and the active compound is chemically fragile, poorly absorbed, and not reliably selective for cancer cells. Reports that it spares healthy cells are directly contradicted by other laboratory work. For everyday use, lemongrass as food or mild tea is inexpensive and generally safe, with the main cautions being skin allergy, stomach upset, blood-sugar lowering, and effects at high doses. The most important consideration is that the evidence does not support using lemongrass in place of treatments known to work, and much about whether it does anything useful in the body remains genuinely uncertain. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**